Viking Global Cuts BridgeBio Stake After Exec Exit

Viking Global Investors LP and its affiliated reporting persons filed Amendment No. 11 to their Schedule 13D regarding BridgeBio Pharma, Inc. (BBIO) to report a decrease in their holdings and a change in the reporting group. Effective March 31, 2026, David C. Ott retired from his roles as Advisory Director of Viking Global Investors LP and Executive Committee Member of its general partner entities. Consequently, Mr. Ott is no longer considered a beneficial owner of the reported shares and has been removed as a reporting person. Between February 18 and February 23, 2026, Viking Global Opportunities Illiquid Investments Sub-Master LP executed several open-market sales totaling 1,183,933 shares at prices ranging from approximately $67.10 to $76.46 per share. Following these transactions and the administrative removal of Mr. Ott, the remaining reporting persons, including O. Andreas Halvorsen and Rose S. Shabet, beneficially own 11,842,434 shares of common stock, representing approximately 6.1% of the outstanding class.